Dose-finding Study of BP-C1 in Patients With Stage IV Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

June 27, 2009

Primary Completion Date

January 4, 2011

Study Completion Date

January 4, 2011

Conditions
Metastatic Breast CancerStage IV Breast Cancer
Interventions
DRUG

BP-C1

"BP-C1, 0.05% solution for injection, will be administered intramuscularly once per day. The cumulative dose range will be 0.64-1.12 mg/kg body weight depending on design level (design level 1-3). The daily dose range will be 0.02-0.035 mg/kg body weight (0.04-0.07 mL/kg) depending on design level (design level 1-3).~Dose level 1: 0.02 mg/kg body weight (0.04 mL/kg) intramuscularly once daily for 32 consecutive days; dose level 2: 0.03 mg/kg body weight (0.06 mL/kg) intramuscularly once daily for 32 consecutive days; dose level 3: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days.~Changes in the cumulative dose of BP-C1 between patients in the sequence are predefined and will be adjusted by escalation/deescalation rules based on changes in toxicity observed in the previous design level.~The duration of BP-C1 treatment will be 32 days."

Trial Locations (3)

Unknown

Sanglah University Hospital, Bali

National Taiwan University Hospital, Taipei

Siriraj Hospital, Mahidol University, Bangkok

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Meddoc

OTHER

collaborator

Norwegian University of Life Sciences

OTHER

collaborator

Meddoc Research Indonesia Ltd

UNKNOWN

collaborator

Meddoc Research Taiwan Ltd

UNKNOWN

lead

Meabco A/S

INDUSTRY

NCT04298333 - Dose-finding Study of BP-C1 in Patients With Stage IV Breast Cancer | Biotech Hunter | Biotech Hunter